Gilead hires Roche’s pharma chief Daniel O’Day as CEORoche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO Share XGilead hires Roche’s pharma chief Daniel O’Day as CEOhttps://pharmaphorum.com/news/gilead-hires-roches-pharma-chief-daniel-oday-as-ceo/
NICE gives final seal of approval for Gilead’s CAR-T in NHLNICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with Share XNICE gives final seal of approval for Gilead’s CAR-T in NHLhttps://pharmaphorum.com/news/nice-gives-final-seal-of-approval-for-gileads-car-t-in-nhl/
AZ’s cancer drug fails again, Roche’s rival gets new useAstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved Share XAZ’s cancer drug fails again, Roche’s rival gets new usehttps://pharmaphorum.com/news/azs-cancer-imfinzi-fail/
Nearly 300 gene and cell therapies in development – reportPharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting Share XNearly 300 gene and cell therapies in development – reporthttps://pharmaphorum.com/news/nearly-300-gene-and-cell-therapies-in-development-report/
Cancer, genomics and personalised medicine: Modelling the future of oncologyOverview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in Share XCancer, genomics and personalised medicine: Modelling the future of oncologyhttps://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
EU approves Kyowa Kirin’s drug for rare lymphomaThe European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is Share XEU approves Kyowa Kirin’s drug for rare lymphomahttps://pharmaphorum.com/news/eu-approves-kyowa-kirins-drug-for-rare-lymphoma/
Bayer/Loxo drug approved in cancers with certain mutationThe FDA has approved Bayer and Loxo’s Vitravki (larotrectinib) for adults and children whose cancers have a specific Share XBayer/Loxo drug approved in cancers with certain mutationhttps://pharmaphorum.com/news/bayer-loxo-drug-approved-in-cancers-with-certain-mutation/
NHS lags best performers in cancer care – reportThe performance of NHS cancer services in England is lagging behind those of comparable countries, according to a Share XNHS lags best performers in cancer care – reporthttps://pharmaphorum.com/news/nhs-lags-best-performers-in-cancer-care-report/
